Safinamide as Add-on Therapy – Moving Beyond Dopamine for a Multifaceted Approach in Parkinson’s Disease
Jaime Kulisevsky, Paolo Calabresi
Dopamine deficiency resulting from the progressive loss of nigrostriatal dopaminergic cells leads to the motor and non-motor impairments associated with Parkinson’s disease (PD). Treatment strategies are focused on dopaminergic replacement therapy. Levodopa monotherapy may be successful in addressing motor symptoms in early-onset patients and may be optimised by adding on other dopamine-potentiating agents such as […]